Braun Stacey Associates Inc. Has $29.96 Million Stock Holdings in Ascendis Pharma A/S $ASND

Braun Stacey Associates Inc. lifted its position in shares of Ascendis Pharma A/S (NASDAQ:ASND) by 10.0% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 130,992 shares of the biotechnology company’s stock after purchasing an additional 11,897 shares during the period. Braun Stacey Associates Inc.’s holdings in Ascendis Pharma A/S were worth $29,962,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds also recently made changes to their positions in ASND. ARS Investment Partners LLC boosted its position in Ascendis Pharma A/S by 20.0% during the 1st quarter. ARS Investment Partners LLC now owns 209,456 shares of the biotechnology company’s stock worth $47,909,000 after buying an additional 34,845 shares during the period. Corient Private Wealth LLC grew its holdings in Ascendis Pharma A/S by 17.7% during the 4th quarter. Corient Private Wealth LLC now owns 3,393 shares of the biotechnology company’s stock worth $724,000 after acquiring an additional 510 shares during the last quarter. Caitong International Asset Management Co. Ltd acquired a new position in Ascendis Pharma A/S in the 4th quarter valued at approximately $42,000. Seven Fleet Capital Management LP acquired a new position in Ascendis Pharma A/S in the 4th quarter valued at approximately $1,209,000. Finally, Dorsey Wright & Associates increased its position in Ascendis Pharma A/S by 3.2% in the 4th quarter. Dorsey Wright & Associates now owns 8,504 shares of the biotechnology company’s stock valued at $1,813,000 after acquiring an additional 263 shares during the period.

Insider Buying and Selling at Ascendis Pharma A/S

In related news, insider Flemming Steen Jensen sold 19,460 shares of the business’s stock in a transaction on Monday, May 11th. The shares were sold at an average price of $238.49, for a total value of $4,641,015.40. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Jean Jacques Bienaime purchased 400 shares of the business’s stock in a transaction on Tuesday, May 26th. The shares were purchased at an average cost of $237.80 per share, for a total transaction of $95,120.00. Following the transaction, the director directly owned 400 shares of the company’s stock, valued at approximately $95,120. The trade was a ∞ increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Corporate insiders own 40.00% of the company’s stock.

Ascendis Pharma A/S Stock Down 0.3%

Ascendis Pharma A/S stock opened at $260.75 on Friday. The company has a debt-to-equity ratio of 0.79, a quick ratio of 0.72 and a current ratio of 1.00. Ascendis Pharma A/S has a 52-week low of $160.86 and a 52-week high of $271.89. The firm has a 50 day moving average price of $232.43 and a two-hundred day moving average price of $225.66. The firm has a market cap of $16.27 billion, a price-to-earnings ratio of 30.08 and a beta of 0.39.

Ascendis Pharma A/S (NASDAQ:ASND) last issued its quarterly earnings results on Thursday, May 7th. The biotechnology company reported $0.32 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.21 by $0.11. The firm had revenue of $285.45 million during the quarter, compared to analyst estimates of $362.47 million. Equities analysts predict that Ascendis Pharma A/S will post 4.55 EPS for the current year.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on ASND. Jefferies Financial Group began coverage on shares of Ascendis Pharma A/S in a report on Monday, March 16th. They set a “buy” rating and a $290.00 price target on the stock. Royal Bank Of Canada increased their price objective on Ascendis Pharma A/S from $250.00 to $275.00 and gave the company an “outperform” rating in a report on Monday, March 2nd. Evercore reaffirmed an “outperform” rating and set a $329.00 target price on shares of Ascendis Pharma A/S in a research report on Friday, May 15th. Wedbush reaffirmed an “outperform” rating and set a $273.00 target price on shares of Ascendis Pharma A/S in a report on Thursday, April 9th. Finally, Wells Fargo & Company reduced their price target on Ascendis Pharma A/S from $330.00 to $326.00 and set an “overweight” rating on the stock in a research report on Friday, May 8th. Two analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average price target of $295.39.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S is a Denmark‐based biopharmaceutical company focused on developing innovative therapies for rare endocrine diseases. Founded in 2015 and headquartered in Hellerup, the company leverages its proprietary TransCon drug delivery platform to create long‐acting prodrugs designed to improve safety, efficacy and patient convenience. Ascendis Pharma maintains research and development operations in Europe and the United States, with clinical studies spanning North America, Europe and Asia.

The company’s lead product, lonapegsomatropin (Skytrofa®), is a once‐weekly growth hormone therapy approved by the U.S.